布拉氏酵母菌联合双歧杆菌三联活菌胶囊治疗儿童病毒性腹泻的疗效观察

Saccharomyces Boulardii Combined with Bifid-triple Viable Capsules in Children with Viral Diarrhea

目的观察布拉氏酵母菌联合双歧杆菌三联活菌胶囊治疗儿童病毒性腹泻的疗效。方法选择2010年6月—2012年12月在本院住院的小于5岁的病毒性腹泻患儿382例,按随机数字表法分为布拉氏酵母菌组(常规治疗+布拉氏酵母菌,n=92)、双歧杆菌三联活菌胶囊组(常规治疗+双歧杆菌三联活菌胶囊,n=113)、联合用药组(常规治疗+布拉氏酵母菌+双歧杆菌三联活菌胶囊,n=114)和对照组(常规治疗,n=63),治疗72 h后比较各组的治疗效果。结果 4组患者治疗72 h的临床疗效间差异有统计学意义(Hc=23.843,P=0.000),其中联合用药组与布拉氏酵母菌组、双歧杆菌三联活菌胶囊组及对照组间比较,差异均有统计学意义(P<0.05),布拉氏组和双歧杆菌三联活菌胶囊组间差异无统计学意义(P>0.05)。结论布拉氏酵母菌与双歧杆菌三联活菌胶囊两药治疗儿童病毒性腹泻的疗效相近,两药联合应用的疗效优于单独应用。

Objective To study the treatment efficacy of saccharomyces boulardii combined with Bifid - triple viable capsules on viral diarrhea in children. Methods A total of 382 patients （below 5 years old） with viral diarrhea admitted to this hospital from June 2010 to December 12 were divided randomly into groups A （ conventional treatment combined with saccharomy- ces boulardii）, B （conventional treatment combined with bifid -triple viable capsules）, C （conventional treatment combined with saccharomyces boulardii and bifid - triple viable capsules）, control （ conventional treatment）. Therapeutic effects were compared between 4 groups after 72 h of treatment. Results There was significant difference in 72 h - therapeutic effect between 4 groups （Hc = 23. 843, P = 0. 000）, between groups C and A, B, control （P 〈 0. 05 ）, but there was not between groups A and B （ P 〉 0. 05 ）. Conclusion The therapeutic effect of saccharomyces boulardii is similar to that of bifid - triple viable cap- sules in treatment of children with viral diarrhea and their combined application is more effective than their single uses.